

HEMATOLOGY
PAPER-III

HEM/D/17/48/III

Time : 3 hours
Max. Marks :100

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space
- Answer all the parts of a single question together.
- Start the question to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. WHO classification of acute leukemia 2016: 4+3+3
 - a) What are the changes in ALL?
 - b) What are germ line malignancy?
 - c) How this classification is better than 2008 classification?
2. Thalassemia: 3+3+4
 - a) Monitoring iron overload
 - b) Long term endocrinological complications and their management
 - c) Hematopoietic stem cell transplant in thalassemia
3. Allogenic hematopoietic stem cell transplantation (HSCT): 4+2+4
 - a) Haploidentical HSCT
 - b) Role of killer immunoglobulin like receptors.
 - c) Its role in therapy of AML.
4.
 - a) Classification of vWD
 - b) Diagnosis of subtypes
 - c) Management of vWD 3+3+4
5. Hemophilia: 3+3+2+2
 - a) Diagnosis of coagulations factor defects.
 - b) Newer FVIII replacement options.
 - c) How do you decide which factors to use?
 - d) Management of hemophiliac joint arthropathy
6. Hodgkin's lymphoma: 3+3+4
 - a) Role of PET-CT.
 - b) Risk adapted approach in the management of Hodgkin's lymphoma.
 - c) Place of hematopoietic stem cell transplantation in the management algorithm.

- | | | |
|-----|---|-------|
| 7. | a) Lab approach to diagnose inherited thrombophilia.
b) ISTH guidelines for management of anti-phospholipic syndrome
c) Newer anti coagulants | 3+4+3 |
| 8. | a) Causes of acquired platelet dyfunctions.
b) Newer anti platelet agents
c) Lab monitoring of anti platelet agents. | 3+4+3 |
| 9. | CML:
a) How will you manage CML patient?
b) Imatinib resistance.
c) International standardization of BCR-ABL. | 6+2+2 |
| 10. | a) Approach to treatment with newer agents in multiple myeloma
b) Therapeutic strategies in sickle cell anemia
c) Optimizing therapy in follicular lymphoma | 4+3+3 |
